BioPorto A/S (CPH:BIOPOR)
Denmark
· Delayed Price · Currency is DKK 1.302
+0.012 (0.93%)
Aug 15, 2025, 4:59 PM CET
BioPorto Revenue
BioPorto had revenue of 10.59M DKK in the quarter ending June 30, 2025, with 15.12% growth. This brings the company's revenue in the last twelve months to 35.84M, up 5.94% year-over-year. In the year 2024, BioPorto had annual revenue of 36.24M with 17.07% growth.
Revenue (ttm)
35.84M
Revenue Growth
+5.94%
P/S Ratio
16.52
Revenue / Employee
746.67K
Employees
48
Market Cap
591.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.24M | 5.29M | 17.07% |
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 311.94B |
| Coloplast | 27.79B |
| Genmab | 23.16B |
| Demant | 22.59B |
| ALK-Abelló | 5.71B |
| H. Lundbeck | 23.52B |
| Ambu A/S | 5.83B |
| Zealand Pharma | 9.11B |
BioPorto News
- 1 day ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - GlobeNewsWire
- 1 day ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - Benzinga
- 17 days ago - BioPorto A/S to host an investor webcast on the results for the first half of 2025 - GlobeNewsWire
- 18 days ago - BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. - GlobeNewsWire
- 2 months ago - BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy - GlobeNewsWire
- 3 months ago - BioPorto A/S to host first quarter 2025 earnings webcast for investors - GlobeNewsWire
- 4 months ago - BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million - GlobeNewsWire
- 4 months ago - BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes - GlobeNewsWire